LifeVantage Corporation LFVN 深 滬
已收盤 02-06 16:00:00 美东时间
5.03
+0.410
+8.87%
華盛通- 最 高5.12
- 今 開4.58
- 成交量 49.66万股
- 最 低 4.58
- 昨 收 4.62
- 總市值 6435.06万
- 52周最高 19.105
- 市盈率 靜 6.66
- 換手率 3.88%
- 52周最低 3.90
- 委 比 68.49%
- 總股本 1279.34万
- 歷史最高 27.205
- 量 比 1.05
- 振 幅 11.69%
- 歷史最低 0.445
- 每 手 1
- 風險率 3.69%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Lifevantage shares are trading lower after the company reported worse-than-expected Q2 sales results and cut its FY26 guidance below estimates.
Lifevantage shares are trading lower after the company reported worse-than-expe...
02-05 05:58
LifeVantage declares $0.045 dividend
LifeVantage (LFVN) declares $0.045/share quarterly dividend, in line with previous. Forward yield 3.24% Payable March 16; for shareholders of record March 2; ex-div March 2. See LFVN Dividend Scorecar...
02-05 05:46
LifeVantage CEO Steve Fife Intends To Retire In April
LifeVantage Corporation® (Nasdaq: LFVN), a leading health and wellness company with products designed to activate optimal health at the cellular level, today announced that after nine years at LifeVantage, Steve
02-05 05:38
Lifevantage Lowers FY2026 Adj EPS Guidance from $1.00-$1.15 to $0.60-$0.80 vs $1.05 Est; Lowers FY2026 Sales Guidance from $225.000M-$240.000M to $185.000M-$200.000M vs $227.507M Est
Lifevantage (NASDAQ:LFVN) lowers FY2026 Adj EPS guidance from $1.00-$1.15 to $0.60-$0.80 vs $1.05 analyst estimate. Lowers FY2026 sales outlook from $225.000 million-$240.000 million to $185.000 million-$200.000 million
02-05 05:08
Earnings Scheduled For February 4, 2026
Companies Reporting Before The Bell • Oaktree Specialty Lending (NASDAQ:OCSL) i...
02-04 19:11
LifeVantage to Announce Second Quarter Fiscal Year 2026 Results on February 4, 2026
LifeVantage Corporation (Nasdaq: LFVN) announced it will release its second quarter financial results ending December 31, 2025, after market close on February 4, 2026. A conference call for investors will be held at 2:30 p.m. Mountain Time (4:30 p.m. Eastern Time) the same day. Investors can join the call by dialing (877) 704-4453 (U.S.) or (201) 389-0920 (international), or via live webcast on the company's Investor Relations website. A replay o...
01-21 21:05
LifeVantage Appoints Seasoned Technology Executive Mike Edwards as Chief Technology Officer to Drive Digital Innovation
LifeVantage appoints Mike Edwards as Chief Technology Officer, leveraging his 25 years of experience to drive digital transformation and enhance technology solutions. Edwards, known for enterprise-wide technology initiatives, will focus on scaling infrastructure, improving customer experiences, and supporting the company's growth strategy. LifeVantage, a leader in nutrigenomics, offers products designed to activate cellular health and operates a ...
01-07 21:05
LifeVantage to Participate in the 28th Annual ICR Conference
LifeVantage Corporation (LFVN) announced that its CEO, Steve Fife, and CFO, Carl Aure, will present at the 28th Annual ICR Conference in Orlando on January 12, 2026. The presentation will be webcast on the company’s Investor Relations website. LifeVantage, a leader in nutrigenomics, offers products designed to activate health at the cellular level, including Protandim® and other science-backed activators. The company, founded in 2003, is headquar...
01-06 21:05
LifeVantage to Participate in Water Tower Fireside Chat on Thursday, December 11, 2025
LifeVantage Corporation (Nasdaq: LFVN) announced that CEO Steve Fife and CFO Carl Aure will participate in the Water Tower Fireside Chat Series on December 11, 2025. The webcast will begin at 2:00 p.m. Eastern Time and is open to all investors. Interested parties can register through the provided links. LifeVantage, a leader in nutrigenomics, offers products like the Protandim® family of products and TrueScience® Liquid Collagen. Founded in 2003,...
2025-12-10 13:00
LifeVantage Trial Results From New In Vitro Demonstrates All 14 Peptides Influences In Desired Direction
LifeVantage Corporation® (NASDAQ:LFVN), a leading health and wellness company with products designed to activate optimal health processes at the cellular level, today announced new in vitro study results for its
2025-11-12 21:08
